Table 2. Diagnostic value of BALF MMP-2 and TIMP-2 in lung cancer.
| AUC | Cut-off (ng/ml) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |
|---|---|---|---|---|---|---|
| MMP-2 | ||||||
| Total | 0.7536 | 1.479 | 75.0% | 62.5% | 70.1% | 67.6% |
| SCC | 0.7458 | 1.794 | 77.8% | 67.5% | 51.90% | 87.1% |
| ADC | 0.7708 | 1.643 | 77.8% | 65.0% | 50.00% | 86.7% |
| SCLC | 0.7396 | 0.906 | 100% | 50.0% | 37.5% | 100% |
| TIMP-2 | ||||||
| Total | 0.6219 | 2.421 | 62.5% | 57.5% | 63.8% | 56.1% |
| SCLC | 0.6229 | 2.421 | 66.7% | 57.5% | 32.0% | 85.2% |
BALF, bronchoalveolar lavage fluid; MMP-2, metal matrix proteinase 2; TIMP-2, tissue inhibitor of metalloproteinase 2; AUC, area under the curves; SCC, squamous cell carcinoma; ADC, adenocarcinoma; SCLC, small-cell lung cancer; PPV: positive predictive value; NPV: negative predictive value.